{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0006954",
      "entity_text" : "inflammation",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:9875401",
      "entity_text" : "rivaroxaban",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Conclusion Anticoagulation with rivaroxaban reduced levels of key inflammation and coagulation biomarkers to a similar extent as VKAs, with the exception of F1.2.",
  "reading_complete" : "2020-08-02T12:47:38Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T12:42:14Z",
  "trigger" : "reduced",
  "evidence" : [ "rivaroxaban reduced levels of key inflammation" ],
  "pmc_id" : "6978177",
  "score" : 0
}